Neurology: Guidelines
SNM Practice Guideline for Brain Death Scintigraphy 2.0 (2012)
The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion imaging to assist in confirming the diagnosis of brain death. Several 99mTc-labeled agents may be used, including 99mTc-ethyl cysteinate dimer (99mTc-ECD), 99mTc-hexamethylpropylene amine oxime (99mTc-HMPAO) and 99mTc-diethylenetriaminepentaacetic acid (99mTc-DTPA).
SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0 (2011)
The purpose of this information is to assist health care professionals in performing, interpreting, and reporting the results of DaT imaging with 123I-ioflupane SPECT.
SNM Procedure Guideline for FDG PET Brain Imaging (2009)
The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of [18F]FDG brain metabolic imaging. The document considers the work of previous guideline organizations such as the German Inter Disciplinary Consensus Conference on Clinical Brain PET, The Austrian Guideline for the Use of FDG-PET in Neurology and Psychiatry, The Society of Nuclear Medicine Procedure Guidelines for Tumor Imaging Using [18F]FDG, The Society of Nuclear Medicine Brain Imaging Council and by individual experts throughout the world.
SNM Procedure Guideline for Brain Perfusion SPECT Using Tc-99m Radiopharmaceuticals (2009)
The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion SPECT studies using 99mTc radiopharmaceuticals, such as unstabilized 99mTc-exametazime (HMPAO), stabilized 99mTc-HMPAO and 99mTc-bicisate (ethyl cystine dimer [ECD]).
EANM Procedure Guidelines for Brain Perfusion SPECT using Tc-99m-labelled Radiopharmaceuticals (2009)
These guidelines summarize the views of the European Association of Nuclear Medicine
Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion SPECT studies using 99mTc-labelled radiopharmaceuticals. The aim is to achieve a high quality standard of brain perfusion SPECT imaging, which can increase the diagnostic impact of this technique in neurological and psychiatric practice.
EANM Procedure Guidelines for Brain Imaging using F-18-FDG (2009)
The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of F-18-fluoro-2-deoxyglucose (18FDG)-PET imaging of the brain. Aim is to help in achieving a high quality standard of FDG imaging, which allows to increase the diagnostic impact of this technique in neurological and psychiatric practice.
EANM Procedure Guidelines for Brain Tumour Imaging using Labelled Amino Acid Analogues (2006)
The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of radiolabelled amino acid analogues for PET or SPECT imaging of brain tumours.
These guidelines deal with the indications, assessment, processing, interpretation and reporting of dopamine transporter (DAT) SPECT investigations using the commercially available radiopharmaceuticals [123I]β-CIT and [123I]FP-CIT.
EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands (2009)
These guidelines deal with the indications, assessment, processing, interpretation and reporting of dopamine D2 receptor SPECT and PET studies using the commercially available radiopharmaceuticals [123I]-IBZM and [123I]-epidepride, as well as [11C]-raclopride, [18F]fallypride and DMFP.